InVivo Therapeutics Holdings Corp. (NVIV)
-OTC BB 2.94 May 23, 3:59PM EDT|Pre-Market
:
NaN
| Prev Close: | 2.94 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 6.00 |
|---|
| Beta: | 0.61 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.25 - 3.79 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 265,456 |
|---|
| Market Cap: | 194.61M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.19 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements aEDGAR Online(Thu, May 23)
- CORRECTING and REPLACING InVivo Therapeutics Announces Webcast for Annual Shareholders Meeting to Be Held on May 23rdBusiness Wire(Tue, May 21)
- Interview with InVivo Therapeutics’ CEO to be Aired on Boston’s NPR Station WBUR This MorningBusiness Wire(Tue, May 21)
- INVIVO THERAPEUTICS HOLDINGS CORP. FinancialsEDGAR Online Financials(Fri, May 17)
- InVivo Therapeutics Announces Webcast for Annual Shareholders Meeting to Be Held on May 23rdBusiness Wire(Fri, May 17)
- InVivo Therapeutics Sponsors 8th Annual Working 2 Walk Spinal Cord Injury SymposiumBusiness Wire(Thu, May 16)
- 2 Medical Device Companies With Revolutionary Platformsat Seeking Alpha(Mon, May 13)
- InVivo Therapeutics Reports First Quarter 2013 Financial Results, Provides Business UpdateBusiness Wire(Thu, May 9)
- INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- InVivo Therapeutics Announces Call Notice for Exercise of Warrants and Partial Termination of Warrant Exchange OfferBusiness Wire(Fri, May 3)
- InVivo Therapeutics Named a 2013 “Best Places to Work” Winner by Boston Business JournalBusiness Wire(Thu, May 2)
- InVivo Therapeutics’ CEO Scheduled to Appear on FOX Business Network’s “Varney & Company”Business Wire(Mon, Apr 29)
- Why I Think InVivo Is Under-Valuedat Seeking Alpha(Mon, Apr 29)
- InVivo Therapeutics’ CEO Scheduled to Appear on Business News Network’s “The Close” in CanadaBusiness Wire(Fri, Apr 26)
- InVivo Enters Commercialization Phase, Adds John A. McCarthy to Board of DirectorsBusiness Wire(Tue, Apr 23)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.31 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Invivo Therapeutics Holdings Corp., a development stage company, focuses on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries, peripheral nerve injuries, and other neurotrauma conditions.
View More 
0.08%